Dong Ki Lee

Dong Ki Lee

Auto-generated profile, based on publicly available information

Dong Ki Lee

Department of Pharmacology, Yonsei University College of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
YBYeong Hak Bang
Yeong Hak Bang
CLChoong-Kun Lee
Choong-Kun Lee
KBKyunghye Bang
Kyunghye Bang
HKHyung-Don Kim
Hyung-Don Kim
KKKyu-pyo Kim
Kyu-pyo Kim
CYChanghoon Yoo
Changhoon Yoo
Purpose: Recently, anti-programmed cell death-1/anti-programmed cell death ligand-1 (anti-PD1/L1) immunotherapy has been demonstrated for its efficacy when combined with cytotoxic chemotherapy in randomized phase 3 trials for advanced biliary tract cancer (BTC). However, no biomarker predictive of benefit has been established for anti-PD1/L1 in BTC. Here, we evaluated tumor-infiltrating lymphocytes (TIL) using artificial intelligence-powered immune phenotype (AI-IP) analysis in advanced BTC treated with anti-PD1. Experimental Design: Pretreatment hematoxylin and eosin (H&E)–stained whole-slide images from 339 patients with advanced BTC who received anti-PD1 as second-line treatment or beyond, were employed for AI-IP analysis and correlative analysis between AI-IP and efficacy outcomes with anti-PD1. Next, data and images of the BTC cohort from The Cancer Genome Atlas (TCGA) were additionally analyzed to evaluate the transcriptomic and mutational characteristics of various AI-IP in BTC. Results: Overall, AI-IP were classified as inflamed [high intratumoral TIL (iTIL)] in 40 patients (11.8%), immune-excluded (low iTIL and high stromal TIL) in 167 patients (49.3%), and immune-desert (low TIL overall) in 132 patients (38.9%). The inflamed IP group showed a substantially higher overall response rate compared with the noninflamed IP groups (27.5% vs. 7.7%, P < 0.001). Median overall survival and progression-free survival were significantly longer in the inflamed IP group than in the noninflamed IP group (OS, 12.6 vs. 5.1 months; P = 0.002; PFS, 4.5 vs. 1.9 months; P < 0.001). In the TCGA cohort analysis, the inflamed IP showed increased cytolytic activity scores and IFNγ signature compared with the noninflamed IP. Conclusions: AI-IP based on spatial TIL analysis was effective in predicting the efficacy outcomes in patients with BTC treated with anti-PD1 therapy. Further validation is necessary in the context of anti-PD1/L1 plus gemcitabine–cisplatin.

1 January 2024 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
DLDong Ki Lee
Dong Ki Lee
JOJongwook OH
Jongwook OH
HPHyun Woo Park
Hyun Woo Park
HGHeon Yung Gee
Heon Yung Gee
Lee DK, et al. J Korean Med Sci. 2024 May;39(19):e156. https://doi.org/10.3346/jkms.2024.39.e156

12 May 2026 in Molecules and Cells
Verified
Journal Article
Open access
DLDong Ki Lee
Dong Ki Lee
JOJongwook Oh
Jongwook Oh
SLSoyeon Lee
Soyeon Lee
HHHyunbin D. Huh
Hyunbin D. Huh
YSYujin Sub
Yujin Sub
HGHeon Yung Gee
Heon Yung Gee
Melanoma metastasis involves dynamic cellular reprogramming that enables tumor cells to survive detachment and disseminate to distant organs. We investigated the role of adherent-to-suspension transition (AST) in melanoma metastasis, examining its dynamics during metastatic dissemination and its relationship with epithelial-to-mesenchymal-like transition (EMT-like transition). Our findings reveal that AST genes, IKZF1, IRF8, and NFE2, critically modulate anchorage dependence through the regulation of cell adhesion and survival pathways. AST gene expression exhibits dynamic plasticity throughout the metastatic cascade, peaking in circulating tumor cells and reverting in established metastases. Clonal phylogenetic reconstruction reveals that AST-high circulating tumor cell clones possess enhanced metastatic capacity and dominate distant lesions. Notably, AST enhances metastatic capabilities and invasiveness in melanoma independently of EMT-like transition. Spatial analysis further indicated that AST-positive tumor cells preferentially localize near blood vessels, suggesting a facilitating role in blood-borne metastasis. These findings provide new insights into the mechanisms driving melanoma metastasis and highlight AST as a key factor contributing to tumor cell plasticity and dissemination.

15 July 2025 in Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
DLDong Ki Lee
Dong Ki Lee
CLChoong-Kun Lee
Choong-Kun Lee
HKHyo Song Kim
Hyo Song Kim
SSSun Jin Sym
Sun Jin Sym
DZDae Young Zang
Dae Young Zang
MJMin Kyu Jung
Min Kyu Jung
Purpose The nProfiler 1 Stomach Cancer Assay (nProfiler1), designed to predict responses to fluorouracil-based adjuvant chemotherapy, measures the expression of four gastric cancer target genes (GZMB, WARS, SFRP4, and CDX1). The randomized phase III POST trial aimed to compare the efficacies of two adjuvant S-1-based doublet chemotherapies: S-1 plus cisplatin (SP) and S-1 plus docetaxel (DS). This study aimed to validate the nProfiler1 assay using a distinct cohort from the POST trial.Materials and Methods The nProfiler1 assay stratifies patients into three groups (low-risk, intermediate-risk, and high-risk) using the prognostic single-patient classifier and two groups (chemotherapy-benefit and no-benefit) using the predictive single-patient classifier. The nProfiler1 assay was applied to formalin-fixed paraffin-embedded slides obtained from the POST trial. Disease-free survival (DFS) and overall survival (OS), including 5-year survival rates, were calculated for the enrolled patients.Results Of the 153 patients in the POST trial, 118 were included in the post-hoc analysis. With a median follow-up of 57.9 months, no significant difference in DFS or OS was observed between the SP and DS groups. The prognostic single-patient classifier predicted the OS in the SP group (p=0.043) but not in the DS group (p=0.594). The chemotherapy-benefit group exhibited numerically longer DFS than the no-benefit group in the SP and DS groups.Conclusion The nProfiler1 assay offers valuable insights into the prognosis and efficacy of adjuvant chemotherapy based on fluorouracil plus platinum doublet regimens but not docetaxel-containing regimens. Further validation with larger patient cohorts and different regimens is warranted.